Analyses of Patient-Reported Outcomes with Mirvetuximab Soravtansine Versus Standard Chemotherapy in the Randomized Phase III FORWARD I Study in Ovarian Cancer
September 2022
in “
Annals of Oncology
”
Studysummary This study observed that MIRV improved gastrointestinal symptoms and other quality of life measures in patients with platinum-resistant ovarian cancer compared to chemotherapy.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on annalsofoncology.org →